Ellis Investment Partners’s Defiance Nasdaq Junior Biotechnology ETF IBBJ Stock Holding History

Ellis Investment Partners’s Portfolio IBBJ Stock Details IBBJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-889	Closed	-$25K	–	846
2021 Q3	$25K	Hold	889	–	–	0.01%	488
2021 Q2	$29K	Sell	889 -213	-19%	-$6.73K	0.01%	468
2021 Q1	$37K	Buy	1,102 +19	+2%	+$690	0.01%	427
2020 Q4	$37K	Sell	1,083 -25	-2%	-$767	0.01%	419
2020 Q3	$28K	Buy	+1,108	New	+$27.9K	0.01%	439

Ellis Investment Partners's IBBJ Position: Q4 2021 in Review

Ellis Investment Partners sold out of Defiance Nasdaq Junior Biotechnology ETF (IBBJ) in Q4 2021, closing a stake of 889 shares — an estimated $25K sold.

Ellis Investment Partners first reported a position in IBBJ in Q3 2020 and held it in 5 quarters. The position peaked at $37K in Q1 2021. 0 funds tracked by Wall St. Rank hold IBBJ as of Q4 2021.

Ellis Investment Partners reported no remaining Defiance Nasdaq Junior Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
Ellis Investment Partners sold 889 Defiance Nasdaq Junior Biotechnology ETF shares in Q4 2021, an estimated $25K.
Ellis Investment Partners first reported a position in Defiance Nasdaq Junior Biotechnology ETF in Q3 2020 and held it in 5 quarters.
Ellis Investment Partners's Defiance Nasdaq Junior Biotechnology ETF position peaked at $37K in Q1 2021.
0 funds tracked by Wall St. Rank held Defiance Nasdaq Junior Biotechnology ETF as of Q4 2021.

Based on Ellis Investment Partners's 13F filing for Q4 2021, filed 1 Feb 2022.